147 related articles for article (PubMed ID: 17929538)
1. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2].
Vuković M; Lapcević M; Kalezić N; Gvozdenović BS
Srp Arh Celok Lek; 2007; 135(7-8):447-52. PubMed ID: 17929538
[TBL] [Abstract][Full Text] [Related]
2. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
3. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
Gastaldelli A; Nauck MA; Balena R
Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
6. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
8. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Hermann LS; Ranstam J; Vaaler S; Melander A
Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
10. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
Buturovic BA; Ristic LB; Narancic AM
Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
[TBL] [Abstract][Full Text] [Related]
11. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.
Uehara MH; Kohlmann NE; Zanella MT; Ferreira SR
Diabetes Obes Metab; 2001 Oct; 3(5):319-25. PubMed ID: 11703421
[TBL] [Abstract][Full Text] [Related]
13. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.
Cravalho CKL; Meyers AG; Mabundo LS; Courville A; Yang S; Cai H; Dai Y; Walter M; Walter PJ; Sharma S; Chacko S; Cogen F; Magge SN; Haymond MW; Chung ST
Diabetologia; 2020 Oct; 63(10):2194-2204. PubMed ID: 32728891
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
15. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
16. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Hother-Nielsen O; Schmitz O; Andersen PH; Beck-Nielsen H; Pedersen O
Acta Endocrinol (Copenh); 1989 Mar; 120(3):257-65. PubMed ID: 2648723
[TBL] [Abstract][Full Text] [Related]
17. Metformin monotherapy for type 2 diabetes mellitus.
Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
[TBL] [Abstract][Full Text] [Related]
18. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
[TBL] [Abstract][Full Text] [Related]
19. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
20. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
